Optimization of dissolution test precision for a ketoprofen oral extended-release product.
暂无分享,去创建一个
S Furlanetto | S Orlandini | P Mura | S Pinzauti | S. Furlanetto | S. Pinzauti | S. Orlandini | F Maestrelli | P. Mura | F. Maestrelli
[1] I. Khan,et al. Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: Challenges and opportunities , 1996 .
[2] M. Siewert. FIP Guidelines for Dissolution Testing of Solid Oral Products (Final Draft, 1995) , 1996 .
[3] S. Qureshi,et al. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[4] Roger Phan-Tan-Luu,et al. Pharmaceutical Experimental Design , 1998 .
[5] K. A. Khan. The concept of dissolution efficiency , 1975, The Journal of pharmacy and pharmacology.
[6] A. Frick,et al. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[7] B. Edgar,et al. Bioavailability from felodipine extended-release tablets with different dissolution properties , 1990 .
[8] P. Quist,et al. Accelerated dissolution testing for improved quality assurance. , 2002, Journal of pharmaceutical and biomedical analysis.
[9] E. Jorgensen,et al. Development of dissolution tests for oral extended-release products , 1998 .